Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Ryuichi Yoshida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3017-7088; OpenAlex author ID A5017878728. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 18

  1. Mitochondrial inhibition enhances the sensitivity of pancreatic ductal adenocarcinoma cells to oncolytic adenovirus. Co-author DOI 10.1016/j.omton.2026.201180↗
  2. p53-armed oncolytic adenovirus induces apoptosis in pancreatic cancer-associated stellate cells via macropinocytosis. Co-author DOI 10.1038/s41417-025-00989-3↗
  3. Predictive Nomogram for Recurrence After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2). Co-author DOI 10.3390/cancers18071181↗
  4. Precise stratification of prognosis in pancreatic ductal adenocarcinoma patients based on pre- and postoperative genomic information. First author DOI 10.1186/s12935-025-03894-9↗
  5. Prognosis Prediction Model After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2). First author DOI 10.3390/cancers17223694↗
  6. Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus. Co-author DOI 10.1038/s41416-024-02583-0↗
  7. Author Correction: Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus. Co-author DOI 10.1038/s41416-024-02850-0↗
  8. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Co-author DOI 10.1007/s00262-022-03334-x↗
  9. Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. Co-author DOI 10.3390/jcm12020465↗
  10. Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. Co-author DOI 10.1016/j.omto.2022.09.003↗
  11. Feasibility of local therapy for recurrent pancreatic cancer. First author DOI 10.1016/j.pan.2022.05.004↗
  12. A Systematic Review of Minimally Invasive Versus Open Radical Antegrade Modular Pancreatosplenectomy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.15523↗
  13. Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis. Co-author DOI 10.1016/j.canlet.2020.10.015↗
  14. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. Co-author DOI 10.1080/15384047.2021.1980312↗
  15. Usefulness of Middle Colic Artery Transposition Technique for Hepatic Arterial Reconstruction in Conversion Surgery for an Initially Unresectable, Locally Adva… Co-author DOI 10.18926/amo/62410↗
  16. Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. Co-author DOI 10.1016/j.omto.2020.03.016↗
  17. The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. Co-author DOI 10.1007/s00535-019-01586-6↗
  18. The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer. Co-author DOI 10.1186/s13046-018-0981-2↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toshiyoshi Fujiwara · 16 shared papers, 2018–2026 · strength 2.74
  2. Yuzo Umeda · 13 shared papers, 2019–2026 · strength 2.05
  3. Kazuya Yasui · 8 shared papers, 2021–2026 · strength 1.47
  4. Shinji Kuroda · 9 shared papers, 2018–2026 · strength 1.40
  5. Kosei Takagi · 7 shared papers, 2021–2026 · strength 1.34
  6. Yoshinori Kajiwara · 4 shared papers, 2022–2026 · strength 0.78
  7. Yasuo Nagai · 3 shared papers, 2025–2026 · strength 0.67
  8. Takeyoshi Nishiyama · 3 shared papers, 2025–2026 · strength 0.67
  9. Ryohei Shoji · 3 shared papers, 2020–2026 · strength 0.58
  10. Masashi Hashimoto · 3 shared papers, 2022–2024 · strength 0.47
  11. Takehiro Okabayashi MD · 2 shared papers, 2025–2026 · strength 0.46
  12. Kenta Sui · 2 shared papers, 2025–2026 · strength 0.46
  13. Kazuyuki Matsumoto · 3 shared papers, 2019–2025 · strength 0.38
  14. Hironari Kato · 3 shared papers, 2019–2025 · strength 0.38
  15. Kazuhiro Yoshida · 2 shared papers, 2021–2022 · strength 0.28
  16. Hiroyuki Araki · 2 shared papers, 2020–2022 · strength 0.23
  17. Hiroyoshi Y. Tanaka · 1 shared paper, 2026 · strength 0.23
  18. Mitsunobu R. Kano · 1 shared paper, 2026 · strength 0.23
  19. Atsushi Masamune · 1 shared paper, 2026 · strength 0.23
  20. Kokichi Miyamoto · 1 shared paper, 2025 · strength 0.19
  21. Yuki Fujii · 1 shared paper, 2025 · strength 0.19
  22. Kazuhiro Yoshida · 1 shared paper, 2025 · strength 0.19
  23. Motoyuki Otsuka · 1 shared paper, 2025 · strength 0.19
  24. Shigeru Horiguchi · 2 shared papers, 2019–2021 · strength 0.18
  25. Hiroki Sato · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.